NASDAQ:SNGX Soligenix Q3 2025 Earnings Report $0.39 +0.01 (+1.53%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Soligenix EPS ResultsActual EPS-$0.58Consensus EPS -$0.63Beat/MissBeat by +$0.05One Year Ago EPSN/ASoligenix Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASoligenix Announcement DetailsQuarterQ3 2025Date11/7/2025TimeBefore Market OpensConference Call DateFriday, November 7, 2025Conference Call Time7:00AM ETUpcoming EarningsSoligenix's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Soligenix Earnings HeadlinesFinancial Review: Cartesian Therapeutics (NASDAQ:RNAC) versus Soligenix (NASDAQ:SNGX)September 22 at 5:15 AM | americanbankingnews.comSoligenix (NASDAQ:SNGX) vs. Pliant Therapeutics (NASDAQ:PLRX) Financial ReviewSeptember 18, 2026 | americanbankingnews.comHas Dylan Jovine lost his mind?SpaceX just signed a deal JPMorgan says could unlock the next phase of the space economy, putting the company on a path toward a 10 trillion valuation. But analyst Dylan Jovine says the biggest winner won't be SpaceX itself. He's identified a small firm, less than half a percent SpaceX's size, that partnered with it directly. An upcoming NASA announcement could be the catalyst. Jovine previously flagged Rocket Lab before it climbed from under 4 dollars to over 151.September 24 at 1:00 AM | Behind the Markets (Ad)SNGX: Applying for Vaccine Development Funding for Ebola VaccineAugust 12, 2026 | finance.yahoo.comSoligenix Announces Recent Updates and Second Quarter 2026 Financial ResultsAugust 7, 2026 | prnewswire.comSoligenix Expands At-the-Market Equity Offering CapacityJune 26, 2026 | tipranks.comSee More Soligenix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Soligenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soligenix and other key companies, straight to your email. Email Address About SoligenixSoligenix (NASDAQ:SNGX), Inc. is a late-stage biopharmaceutical company focused on developing treatments for rare diseases and medical conditions with limited therapeutic options. The company’s programs are organized around two principal areas: specialized therapeutics for inflammatory and dermatologic disorders, and vaccines and countermeasures for serious infectious diseases and biodefense applications. Its lead product candidate, HyBryte™ (synthetic hypericin), is an investigational photodynamic therapy being developed for cutaneous T-cell lymphoma, a form of non-Hodgkin lymphoma that primarily affects the skin. Soligenix has also developed SGX301, the former designation for HyBryte, and maintains additional research programs involving oral and systemic therapies for inflammatory diseases. The company’s biodefense portfolio includes RiVax®, a recombinant ricin toxin vaccine candidate, and ThermoVax®, a technology designed to improve the thermal stability of vaccines and other biologic products. Headquartered in Princeton, New Jersey, Soligenix conducts research and clinical development primarily in the United States while pursuing opportunities for broader application and commercialization of its technologies. The company is led by Christopher J. Schaber, Ph.D., who serves as president and chief executive officer. Soligenix’s products remain subject to clinical development and regulatory review, and availability may vary by program and jurisdiction.View Soligenix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
